Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...

Bristol-Myers Squibb's has become the first company to bring a cardiac myosin inhibitor through to FDA approval, claiming a green light from the US regulator for mavacamten as a therapy for ...

Matt Korda, the associate director of the Nuclear Information Project at the Federation of American Scientists, assisted USA ...

The traditional paradigm of metallic biomaterials requires metals with improved corrosion resistance in the body. A new class ...